GlaxoSmithKline is informing health care professionals of an incident of misbranding of Ziagen (abacavir sulfate) as Combivir (lamivudine/zidovudine). Apparently, counterfeit Combivir labels were used by a third party. Two 60-count misbranded bottles of Combivir tablets (lot number 6ZP9760 with the expiration dates April 2009 and April 2010) contained Ziagen 300 mg tablets. The warning letter noted that the incident appears to be isolated and limited to one pharmacy in California.
12 April 2007